Stiris Research Inc. collaborates on a Investigator Initiated Trial in Frontotemporal Dementia

London, ON — August 17, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced its collaboration with a London, ON hospital and Investigator on their North American Phase II Investigator Initiated trial in Frontotemporal Dementia.

“Collaborating and working alongside a local medical and academic institution is important to Stiris for many reasons, primarily helping to support clinical research and new treatments for patients in our own backyard. Having the opportunity to work closely with an Investigator directly gives us a unique opportunity to have firsthand input into the development of the protocol and study overall and to getting new treatment modalities into patients,” Amanda Carrera, Vice President, Stiris Research Inc.

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language. Frontotemporal dementia is often misdiagnosed as a psychiatric problem or as Alzheimer’s disease. But frontotemporal dementia tends to occur at a younger age, generally between the ages of 40 and 45 (Mayo Clinic, 2017).

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.